3-TIDE
Retatrutide · 10mg · Triple Incretin Receptor Agonist
Triple-axis metabolic
intervention.
Retatrutide represents a landmark advance in incretin pharmacology — the first peptide designed to engage all three principal metabolic receptors simultaneously: GLP-1 (glucagon-like peptide-1), GIP (glucose-dependent insulinotropic polypeptide), and the glucagon receptor. This triple-agonist architecture opens an entirely new dimension of investigation, allowing researchers to dissect the individual and combined contributions of each receptor pathway to outcomes in energy balance, adipose mass, hepatic steatosis, and glycaemic control.
Phase 2 data from Eli Lilly's clinical programme demonstrated mean body weight reductions of up to 24.2% over 48 weeks — figures that substantially exceed both tirzepatide and semaglutide benchmarks in comparative analyses. The addition of glucagon receptor agonism is theorised to drive thermogenesis and hepatic glucose output suppression through pathways distinct from GLP-1/GIP, offering a uniquely powerful platform for exploring the interplay between insulin-sensitising and energy-expending mechanisms. For researchers studying body recomposition, NASH, type 2 diabetes pathophysiology, or the pharmacodynamics of multi-receptor metabolic modulation, 3-TIDE provides an unmatched preclinical research tool.
GLP-1 Agonism
Insulin secretion amplification, gastric emptying suppression, and central appetite regulation. The established backbone of the leading metabolic drug class — now combined with two further mechanisms.
GIP Agonism
Potentiates insulin release in a glucose-dependent manner, modulates bone metabolism, and exhibits adipocyte effects that complement GLP-1 activity — reducing nausea while amplifying efficacy.
Glucagon Receptor Agonism
The differentiating third axis. Drives hepatic glucose output suppression, thermogenesis via brown adipose tissue activation, and lipolysis — enabling body recomposition research at unprecedented depth.
